Key Points- Bristol Myers Squibb believes Alzheimer’s treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in sales across different uses. – Company executives said each treatment type they are studying has multibillion-dollar potential, including Alzheimer’s disease psychosis, agitation and cognition, along […]